Company: Incyte Corporation

Bloomberg ticker: INCY US

Market cap: US$16,227m

Background: Incyte Corporation, a U.S.-based biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics. It operates globally, specializing in oncology and inflammation. Its key products include Jakafi (ruxolitinib), a treatment for certain blood cancers, and Opzelura, a cream for dermatological conditions.
 

World Class Benchmarking of Incyte Corp
 

(Click on image to enlarge)

• Profitable Growth rank of 1 was up compared to the prior period’s 10th rank
• This is World Class performance compared to 350 large Health Care companies worldwide
• Profitability rank of 2 was worse than its Growth rank of 1
• Profitability rank of 2 was up compared to the prior period’s 9th rank
• This is World Class performance compared to peers
• Growth rank of 1 was up compared to the prior period’s 10th rank
• This is World Class performance compared to peers

More By This Author:

Stock Analysis: Maple Leaf Foods
Stock Analysis: Dharma Satya Nusantara
Stock Analysis: LG Electronics